Women have a greater immunological response to effective virological HIV-1 therapy [7]

AIDS

Volumn 17, Issue 13, 2003, Pages 2009-2011

  Finkel, Diana G ^a   John, Genevieve ^a   Holland, Bart ^b   Slim, Jihad ^a   Smith, Stephen M ^a,b  

^a ST MICHAEL S MEDICAL CENTER   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; VIRUS INFECTION; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; VIRAL LOAD;

EID: 0042829389     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200309050-00032     Document Type: Letter

References (7)

1. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC, USA: Department of Health and Human Services; and Oakland, California, USA: Henry J. Kaiser Foundation; 2001.
2. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
3. Evans JS, Nims T, Cooley J, Bradley W, Jagodzinski L, Zhou S, et al. Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997, 175:795-800.
4. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999, 180:666-672.
5. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996, 335:1091-1098.
6. Han X, Lundberg P, Tanamachi B, Openshaw H, Longmate J, Cantin E. Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. J Virol 2001, 75:3048-3052.
7. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999, 341:1865-1873.